Volume 89 Issue 3 | p. 19 | Concentrates
Issue Date: January 17, 2011

Lilly, Boehringer Partner In Diabetes

Department: Business
Keywords: alliance, pharmaceuticals, diabetes

Eli Lilly & Co. and Boehringer Ingelheim will jointly develop a portfolio of diabetes compounds that are in or nearing late-stage development. Lilly will pay $390 million up front to Boehringer Ingelheim, which could also receive up to $820 million in milestone payments related to two oral diabetes agents it will contribute to the alliance. For its two insulin analogs, Lilly could gain $650 million in milestones. If Boehringer chooses to develop Lilly’s anti-TGF-β monoclonal antibody, Lilly would be eligible for up to $525 million more in potential payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment